CPA
FLNA

Cowen Prime Advisors’s Filana Therapeutics FLNA Stock Holding History

Cowen Prime Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$28K Hold
1,143
– – 0.01% 152
2023
Q1 		$27K Hold
1,143
– – 0.01% 153
2022
Q4 		$34K Buy
+1,143
New +$41.1K 0.01% 141

Other funds holding FLNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Cowen Prime Advisors's FLNA Position: Q2 2023 in Review

Cowen Prime Advisors held its Filana Therapeutics (FLNA) position steady in Q2 2023 at 1,143 shares worth $28K. The position accounts for 0.01% of the portfolio, ranked #152.

Cowen Prime Advisors first reported a position in FLNA in Q4 2022 and has held it in 3 quarters since. The position peaked at $34K in Q4 2022. 152 funds tracked by Wall St. Rank hold FLNA as of Q2 2023.

  • Cowen Prime Advisors held 1,143 shares of Filana Therapeutics worth $28K as of Q2 2023.
  • Cowen Prime Advisors left its Filana Therapeutics share count unchanged in Q2 2023.
  • Filana Therapeutics made up 0.01% of Cowen Prime Advisors's portfolio in Q2 2023, its #152 holding.
  • Cowen Prime Advisors first reported a position in Filana Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • Cowen Prime Advisors's Filana Therapeutics position peaked at $34K in Q4 2022.
  • 152 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2023.

Based on Cowen Prime Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.